Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Seniors - 65 +
  • California
  • Glendale


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole
    NCT04121910
    Condition:   Solid Tumour
    Interventions:   Drug: Savolitinib;   Drug: Itraconazole
    Sponsors:   AstraZeneca;   Parexel
    Recruiting
  • Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers
    NCT04074837
    Condition:   Alzheimer Disease
    Interventions:   Drug: NNI-362;   Drug: Placebo
    Sponsors:   Neuronascent, Inc.;   National Institute on Aging (NIA)
    Recruiting
  • A Phase I Study of SB26 in Healthy Volunteers
    NCT03630627
    Condition:   Healthy Volunteers
    Interventions:   Drug: SB26;   Drug: Placebo
    Sponsor:   Samsung Bioepis Co., Ltd.
    Recruiting
  • A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants
    NCT03933488
    Condition:   Healthy Participants
    Interventions:   Drug: TAK-994;   Drug: TAK-994 Placebo
    Sponsor:   Takeda
    Recruiting
  • Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease
    NCT03611569
    Conditions:   Healthy;   Parkinson Disease
    Interventions:   Drug: Lu AF82422;   Drug: Placebo
    Sponsor:   H. Lundbeck A/S
    Recruiting
  • To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Type 2 Diabetes.
    NCT04155645
    Conditions:   Dyslipidemia;   Type 2 Diabetes
    Interventions:   Drug: AZD8233 subcutaneous injection;   Drug: Placebo
    Sponsors:   AstraZeneca;   Parexel
    Recruiting
  • MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
    NCT03072927
    Condition:   Lumbar Spinal Stenosis
    Intervention:   Device: MILD
    Sponsor:   Vertos Medical, Inc.
    Recruiting
  • ECG Belt for CRT Response
    NCT03504020
    Condition:   Heart Failure
    Intervention:   Device: ECG Belt Research System
    Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
    Recruiting
  • A Pivotal Study of the Premia Spine TOPS™ System
    NCT03012776
    Conditions:   Lumbar Spinal Stenosis;   Degenerative Spondylolisthesis
    Interventions:   Device: Total Posterior Spine System (TOPS);   Procedure: Transforaminal Lumbar Interbody Fusion (TLIF)
    Sponsor:   Premia Spine
    Recruiting
  • Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
    NCT04000009
    Condition:   Adjunctive Treatment of Major Depressive Disorder
    Intervention:   Drug: Pimavanserin
    Sponsor:   ACADIA Pharmaceuticals Inc.
    Recruiting
  • Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
    NCT03788746
    Condition:   Urothelial Carcinoma
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting
  • Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer
    NCT03778931
    Condition:   Breast Cancer
    Interventions:   Drug: Elacestrant;   Drug: Standard of Care
    Sponsor:   Radius Pharmaceuticals, Inc.
    Recruiting
  • A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
    NCT03766581
    Conditions:   Acute Ischemic Stroke;   Transient Ischemic Attack (TIA)
    Interventions:   Drug: BMS-986177;   Other: Placebo;   Drug: Clopidogrel;   Drug: Aspirin
    Sponsors:   Bristol-Myers Squibb;   Janssen, LP
    Recruiting
  • A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
    NCT03750643
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: LY3454738;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting
  • DE-117 Spectrum 5 Study
    NCT03697811
    Condition:   Primary Open-angle Glaucoma and Ocular Hypertension
    Intervention:   Drug: DE-117 Ophthalmic Solution
    Sponsor:   Santen Inc.
    Recruiting
  • A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
    NCT04035226
    Condition:   Multiple Myeloma
    Intervention:   Other: No intervention
    Sponsors:   Janssen-Cilag Ltd.;   Legend Biotech
    Recruiting
  • Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (CLARITY-2)
    NCT03968159
    Condition:   Adjunctive Treatment of Major Depressive Disorder
    Interventions:   Drug: Pimavanserin;   Drug: Placebo
    Sponsor:   ACADIA Pharmaceuticals Inc.
    Recruiting
  • A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
    NCT03762850
    Condition:   Immunoglobulin A Nephropathy
    Interventions:   Drug: sparsentan;   Drug: irbesartan
    Sponsor:   Retrophin, Inc.
    Recruiting
  • QUILT 2.023: A Study of N803 in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.
    NCT03520686
    Condition:   Non Small Cell Lung Cancer
    Interventions:   Drug: N-803 + Pembrolizumab;   Drug: Pembrolizumab
    Sponsors:   Altor BioScience;   NantCell, Inc.
    Recruiting
  • QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
    NCT03228667
    Conditions:   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Urothelial Carcinoma;   Head and Neck Squamous Cell Carcinoma;   Merkel Cell Carcinoma;   Melanoma;   Renal Cell Carcinoma;   Gastric Cancer;   Cervical Cancer;   Hepatocellular Carcinoma;   Microsatellite Instability;   Mismatch Repair Deficiency;   Colorectal Cancer
    Interventions:   Drug: ALT-803 + Pembrolizumab;   Drug: ALT-803 + Nivolumab;   Drug: ALT-803 + Atezolizumab;   Drug: ALT-803 + Avelumab
    Sponsor:   Altor BioScience
    Recruiting
  • Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
    NCT04044664
    Condition:   Post-Traumatic Stress Disorder
    Interventions:   Drug: Placebo oral capsule;   Drug: NYX-783
    Sponsors:   Aptinyx;   Premier Research Group plc;   Massachusetts General Hospital
    Recruiting
  • A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
    NCT03834753
    Conditions:   Age-related Macular Degeneration;   Neovascular Age-related Macular Degeneration;   Wet Macular Degeneration
    Interventions:   Biological: bevacizumab;   Biological: ranibizumab
    Sponsor:   Outlook Therapeutics, Inc.
    Recruiting
  • Tenecteplase in Stroke Patients Between 4 and 24 Hours
    NCT03785678
    Condition:   THROMBOLYSIS
    Interventions:   Biological: Tenecteplase;   Other: Placebo
    Sponsor:   Genentech, Inc.
    Recruiting
  • The Object of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
    NCT03739203
    Condition:   Major Depressive Disorder
    Interventions:   Drug: Cariprazine;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
    NCT04026165
    Condition:   Diabetic Kidney Disease
    Interventions:   Drug: SEL;   Drug: Placebo
    Sponsor:   Gilead Sciences
    Recruiting
  • Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
    NCT03891862
    Condition:   Tardive Dyskinesia (TD)
    Interventions:   Drug: Valbenazine;   Drug: Placebo oral capsule
    Sponsor:   Neurocrine Biosciences
    Recruiting
  • Safety and Efficacy of KPI-121 in Subjects With DED
    NCT03616899
    Condition:   Kerato Conjunctivitis Sicca
    Interventions:   Drug: KPI-121 Ophthalmic Suspension;   Drug: Vehicle
    Sponsor:   Kala Pharmaceuticals, Inc.
    Recruiting
  • Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
    NCT02507687
    Conditions:   Glaucoma, Open-Angle;   Ocular Hypertension
    Interventions:   Drug: Bimatoprost SR;   Drug: Sham Bimatoprost SR;   Procedure: Selective Laser Trabeculoplasty;   Procedure: Sham Selective Laser Trabeculoplasty
    Sponsor:   Allergan
    Recruiting
  • A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
    NCT03573297
    Conditions:   Bipolar I Disorder;   Mania;   Depression
    Interventions:   Drug: Cariprazine;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting
  • A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
    NCT03518034
    Conditions:   Hypogonadism;   Cardiovascular Diseases
    Interventions:   Drug: Testosterone;   Drug: Placebo
    Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
    Recruiting
  • Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    NCT03499353
    Condition:   Early Breast Cancer
    Intervention:   Drug: TALAZOPARIB
    Sponsor:   Pfizer
    Recruiting
  • Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
    NCT03443973
    Condition:   Alzheimer's Disease
    Interventions:   Drug: Gantenerumab;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
    NCT03395197
    Condition:   mCRPC
    Interventions:   Drug: Talazoparib with enzalutamide;   Drug: Placebo with enzalutamide
    Sponsors:   Pfizer;   Astellas Pharma Inc
    Recruiting
  • Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure
    NCT03035474
    Condition:   Heart Failure
    Interventions:   Other: Digital Engagement;   Other: Direct Engagement
    Sponsors:   Duke University;   Duke Clinical Research Institute
    Recruiting
  • MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing
    NCT02006069
    Condition:   Heart Failure
    Intervention:   Device: MPP
    Sponsor:   Abbott Medical Devices
    Recruiting
  • Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
    NCT02600507
    Condition:   Bipolar Depression
    Interventions:   Drug: ITI-007;   Drug: Placebo
    Sponsor:   Intra-Cellular Therapies, Inc.
    Recruiting
  • Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
    NCT02876835
    Condition:   Anaemia
    Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
    Sponsor:   GlaxoSmithKline
    Recruiting
  • A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
    NCT02782104
    Condition:   Depressive Disorder, Treatment-Resistant
    Intervention:   Drug: Esketamine Nasal Spray
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
    NCT02446132
    Condition:   Agitation in Patients With Dementia of the Alzheimer's Type
    Intervention:   Drug: AVP-786
    Sponsor:   Avanir Pharmaceuticals
    Recruiting
  • Baroreflex Activation Therapy for Heart Failure
    NCT02627196
    Condition:   Heart Failure
    Interventions:   Device: BAROSTIM NEO® System;   Drug: Medical Management
    Sponsor:   CVRx, Inc.
    Recruiting
  • Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
    NCT01729455
    Condition:   Systemic Lupus Erythematosus
    Interventions:   Biological: BENLYSTA;   Other: SLE treatment
    Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
    Recruiting
  • Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
    NCT00351611
    Condition:   Epilepsies, Partial
    Interventions:   Drug: Lyrica (pregabalin);   Drug: placebo
    Sponsor:   Pfizer
    Recruiting
  • A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
    NCT03093116
    Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsor:   Turning Point Therapeutics, Inc.
    Recruiting
  • A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
    NCT03691662
    Condition:   Glaucoma and Ocular Hypertension
    Interventions:   Drug: DE-117 Ophthalmic Solution;   Drug: Timolol Maleate Ophthalmic Solution 0.5%
    Sponsor:   Santen Inc.
    Recruiting
  • A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
    NCT03517722
    Condition:   Lupus Erythematosus, Systemic
    Interventions:   Drug: Placebo;   Drug: Ustekinumab (approximately 6 mg/kg);   Drug: Ustekinumab 90 mg
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
    NCT03503318
    Condition:   Schizophrenia
    Interventions:   Drug: TV-46000 - A;   Drug: TV-46000 - B;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC